REG - Celadon Pharma. PLC - Result of General Meeting

Celadon PharmaceuticalsAnnouncement

28/07/2025 16:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250728:nRSb8583Sa&default-theme=true

RNS Number : 8583S  Celadon Pharmaceuticals PLC  28 July 2025

28 July 2025

 

Celadon Pharmaceuticals Plc

("Celadon" or the "Company")

Result of General Meeting

 

London, 28 July 2025: Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based
pharmaceutical company focused on the research, cultivation, manufacturing,
and sale of breakthrough cannabis-based medicines, announces that at the
general meeting of the Company held earlier today (the "General Meeting"), all
resolutions put to the Company's shareholders ("Shareholders") were duly
passed.

 

Full details of the poll results are set out below.

 

 Resolutions                                                                Number of votes "For"  % of votes "For"  Number of votes "Against"  % of votes "Against"  Number of votes "Withheld"
 1       Cancellation Resolution                                            45,983,984             85.29             7,927,910                  14.71                 7,020
 2       Adoption of new articles of association of the Company Resolution  45,984,984             85.30             7,926,910                  14.70                 7,020
 3       Re-registration and change of Articles Resolution                  45,990,665             85.31             7,919,370                  14.69                 8,879

 

 

The full text of the Resolutions proposed and passed at the General Meeting
can be found in the Circular containing, inter alia, the Notice of General
Meeting, which was published on 2 July 2025 and is available on the Company's
website www.celadonpharma.com.

 

AIM Cancellation

 

Following approval by Shareholders at the General Meeting, the admission of
the Ordinary Shares to trading on AIM will be cancelled. The Cancellation is
expected to take place at 7:00 a.m. on 8 August 2025 and, accordingly, the
last day of dealings in Ordinary Shares on AIM is expected to be 7 August
2025.

 

The Ordinary Shares are currently suspended from trading on AIM as the Company
has not been able to publish its report & accounts for the year ended 31
December 2024 by 30 June 2025. It is not expected that the Company will be
able to publish its report & accounts for the year ended 31 December 2024
by 7 August 2025 and as such the suspension from trading on AIM is not
expected to be lifted prior to Cancellation.

 

Re-registration as a private company

 

In accordance with the passing of Resolution 3, the Company will re-register
as a private limited company and adopt new articles of association, which is
expected to take place by 15 August 2025.

 

Matched Bargain Facility

 

The Company has made arrangements for the Matched Bargain Facility to assist
Shareholders to trade in the Ordinary Shares from the date of Cancellation, if
the Cancellation Resolution is passed. The Matched Bargain Facility will be
provided by J P Jenkins, which is an appointed representative of Prosper
Capital LLP, which is authorised and regulated by the UK Financial Conduct
Authority. Under the Matched Bargain Facility, Shareholders or persons wishing
to acquire or dispose of Ordinary Shares will be able to leave an indication
with J P Jenkins, through their stockbroker, of the number of Ordinary Shares
that they are prepared to buy or sell and the price at which they are prepared
to do so. In the event that J P Jenkins is able to match that order with an
opposite sell or buy instruction, it would contact both parties and then
effect the bargain (trade). Should the Cancellation become effective, the
Matched Bargain Facility will commence, and details will be made available to
Shareholders on the Company's website. It should be noted, however, that there
is no guarantee as to the liquidity such a facility would afford the Ordinary
Shares post Cancellation.

 

Capitalised terms used but not defined in this announcement shall have the
same meaning given to such terms in the Circular and the announcement dated 2
July 2025.

 

 

 

Enquiries:

 Celadon Pharmaceuticals Plc
 James Short                                               Via Canaccord Genuity Limited
 Canaccord Genuity Limited (Nominated Adviser and Broker)
 Bobbie Hilliam / Andrew Potts                             +44 (0)20 7523 8000

 Global Investment Strategy UK Limited (Joint Broker)      +44 (0)20 7048 9400
 James Sheehan

 

About Celadon Pharmaceuticals Plc

 

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on
the development, production and sale of breakthrough cannabis-based medicines.
Its primary focus is on improving quality of life for chronic pain sufferers,
as well as exploring the potential of cannabis-based medicines for other
conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved
and comprises indoor hydroponic cultivation, proprietary GMP extraction and an
analytical and R&D laboratory. Celadon's Home Office licence allows for
the commercial supply of its pharmaceutical-grade cannabis product. The Group
owns an approved clinical trial using cannabis-based medicinal products to
treat chronic pain in the UK. Celadon also has a minority interest in
early-stage biopharma Kingdom Therapeutics, which is developing a licensed
cannabinoid medicine to treat children with Autism Spectrum Disorder.

 

For further information please visit our website www.celadonpharma.com
(http://www.celadonpharma.com)

 

This announcement contains inside information for the purposes of article 7 of
the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the
Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication
of this announcement, this information is now considered to be in the public
domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMEVLFLEDLBBBX